- Investing Ideas
- /
- Argentinian Pharmaceuticals & Biotech Potentially Undervalued Companies
Argentinian Pharmaceuticals & Biotech Potentially Undervalued Companies
Results
17
3 new
Companies with a Value score of at least 3, ordered by Value score
17 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
MRK | AR$21,400.00 | -4.9% | -1.4% | AR$255.5b | AR$27,882.60 | PE20.8x | E16.0% | 3.2% | ||
GILD | AR$24,625.00 | -2.6% | 20.6% | AR$115.1b | AR$26,347.81 | PE913.7x | E40.6% | 3.3% | ||
BMYD New | €20.60 | n/a | n/a | €117.9b | €21.47 | PS2.5x | E48.8% | 4.1% | ||
BIIB | AR$13,000.00 | -4.9% | -35.1% | AR$22.8b | AR$20,537.58 | PE14.2x | E12.4% | n/a | ||
BMY | AR$20,275.00 | -5.4% | 16.4% | AR$117.9b | AR$21,680.52 | PS2.4x | E48.7% | 4.2% | ||
MRKD | US$20.60 | -6.4% | 12.0% | US$255.5b | US$26.84 | PE20.8x | E16.0% | 3.2% | ||
BIIBD | US$12.70 | 0% | n/a | US$22.8b | US$20.06 | PE14.2x | E12.4% | n/a | ||
NVSD | US$25.00 | -12.0% | n/a | US$177.5b | US$28.68 | PE17.1x | E7.0% | 3.6% | ||
GSKD | US$8.70 | -6.3% | n/a | US$54.7b | US$11.79 | PE21.8x | E23.2% | 4.3% | ||
NVS | AR$26,550.00 | -5.3% | 6.6% | AR$175.8b | AR$30,794.26 | PE16.9x | E7.0% | 3.6% | ||
GSK | AR$9,200.00 | -3.7% | -1.3% | AR$54.7b | AR$12,469.43 | PE21.8x | E23.2% | 4.3% | ||
GILDD | US$23.20 | -3.3% | -3.3% | US$115.1b | US$24.82 | PE913.7x | E40.6% | 3.3% | ||
ROSE | AR$118.75 | -1.0% | 74.6% | AR$5.1b | n/a | PE5x | n/a | n/a | ||
AMGND New | US$9.20 | 1.7% | 4.5% | US$148.2b | US$10.95 | PE34.7x | E18.5% | 3.3% | ||
TMOD | US$28.50 | 0% | n/a | US$205.0b | US$34.77 | PE33.4x | E11.5% | 0.3% | ||
AMGN New | AR$9,830.00 | -4.3% | 4.5% | AR$148.2b | AR$11,697.50 | PE34.7x | E18.5% | 3.3% | ||
TMO | AR$26,100.00 | -2.0% | 11.8% | AR$205.0b | AR$31,928.49 | PE33.3x | E11.5% | 0.3% |
Page 1 of 1